The U.S. Food and Drug Administration (FDA) on October 14 launched a Rare Disease Framework Initiative, an effort to rethink how drugs and biologics for rare diseases are developed and reviewed, and published a white paper setting out six commitments. The agency said only about 5% of rare conditions have an FDA-approved treatment and scheduled a public meeting for October 28 to take comment.

The initiative is led by the FDA’s Rare Disease Innovation Hub, working with the Office of the Commissioner, the Center for Biologics Evaluation and Research (CBER) and the Center for Drug Evaluation and Research (CDER), according to the agency’s announcement. The stated goal is a framework that accounts for each disease, patient needs, the type of product and the evidence that can realistically be generated in small patient populations, rather than a largely uniform approach.

The white paper, titled “A New Framework for Rare Disease Review”, lists six commitments. The FDA says it will:

  • Improve clarity, consistency and predictability through tailored guidance and transparent communication.
  • Bring the patient’s voice in early and at defined milestones.
  • Use outside expertise to tailor regulatory review.
  • Build shared resources, training and institutional knowledge on rare disease development and review.
  • Apply risk-based approaches, especially to chemistry, manufacturing and controls (CMC) review and pre-approval inspections.
  • Promote cutting-edge science, novel methods and innovative statistical approaches.

“Americans with rare diseases cannot afford a regulatory system that treats every condition the same,” Health and Human Services Secretary Robert F. Kennedy Jr. said in the release. Amy Comstock Rick, director of the Rare Disease Innovation Hub, said: “This new framework will enhance consistency and predictability for both sponsors and for patients.”

What the white paper says is wrong today

According to a summary of the paper by Applied Clinical Trials, the FDA argues that small, dispersed patient populations complicate enrollment, natural history data are often sparse, biomarkers may be unvalidated and disease heterogeneity makes study populations hard to define. Placebo-controlled trials and validated surrogate endpoints may be unavailable. The paper says regulatory flexibility has been applied in many cases but not consistently across review divisions, and that fixing that inconsistency is the framework’s central aim.

The same summary reports that about 30 million Americans, roughly one in 10, live with a rare disease, that an estimated 300 million people are affected worldwide across 7,000 to 10,000 conditions, and that roughly half of recent novel approvals at CDER and CBER have been for rare diseases. The white paper cites research finding that the lack of an approved treatment is independently associated with a 21.2% annual increase in total per-patient costs. A 2024 Government Accountability Office report counted 18 rare disease programs at the agency, most of them launched since 2019.

Why it matters

For companies developing rare disease drugs, the practical promise is predictability: knowing earlier what evidence a review division will accept, how manufacturing will be inspected and when patient input will be sought. The FDA listed possible outputs including new or revised guidance, regulatory revisions, staff training and organizational changes. Applied Clinical Trials reported that expected deliverables include revised guidance on endpoints, statistics and trial design, alignment between CDER and CBER, and a reviewer training plan.

For patients, the headline number is the 5% figure. “Patients and families living with rare diseases have few or no approved treatment options,” Acting FDA Commissioner Kyle Diamantas said in the release. Whether a framework changes that depends on what the agency finalizes and how it is applied division by division, which the announcement does not yet specify.

What to watch

The public meeting on October 28 at the FDA’s White Oak campus, facilitated by the Reagan-Udall Foundation for the FDA, is open to patients, advocates, industry and others. After it, the agency plans sector-specific roundtables, requests for information and internal feedback sessions with review teams. The FDA gave no date for a final framework.

The caveats

This is an initiative and a white paper, not a rule or a guidance document; nothing in it changes current review standards. The commitments are stated in general terms, and the announcement gives no timeline for deliverables. The figures on prevalence and costs come from the FDA’s paper and from secondary reporting on it, not from a new study.

This article is for general information and does not replace advice from a qualified clinician. Corrections: email the editor using the address on the Contact page.